📷 Image: Wikimedia Commons / R. Andre Newton ISAF Headquarters Public Affairs O
Business
Jubilant Generics Receives Show-Cause Notice Over ₹105 Crore Demand
✍️ The Economic Times
🗓 28 Aug 2026, 05:37 PM
👁 3
The pharmaceutical company Jubilant Generics has been issued a show‑cause notice by authorities demanding more than ₹105 crore.
Jubilant Generics, a leading Indian pharmaceutical manufacturer, has received a show‑cause notice from regulatory authorities demanding a repayment of over ₹105 crore.
The notice, issued today, requires the company to explain its position regarding the alleged financial discrepancy and to provide the requested amount within a specified period.
While the exact nature of the claim has not been disclosed, the notice underscores the regulatory scrutiny faced by firms in the pharma sector.
Jubilant Generics is expected to respond formally to the notice and may seek to negotiate a settlement or clarification with the authorities.
The case highlights the importance of compliance and transparency for companies operating in highly regulated industries.
The notice, issued today, requires the company to explain its position regarding the alleged financial discrepancy and to provide the requested amount within a specified period.
While the exact nature of the claim has not been disclosed, the notice underscores the regulatory scrutiny faced by firms in the pharma sector.
Jubilant Generics is expected to respond formally to the notice and may seek to negotiate a settlement or clarification with the authorities.
The case highlights the importance of compliance and transparency for companies operating in highly regulated industries.